Overview

The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.

Eligibility

Inclusion Criteria:

        Individuals from the following groups who present for clinical evaluation and assessment of
        PDAC risk at any of the participating sites can be offered participation in the PRECEDE
        database:
        Cohort 1
        Individuals without history of PDAC meeting any of the following criteria:
          1. 2+ relatives with PDAC on same side of family where 2 affected are first degree
             related to each other and at least 1 affected is first degree related to subject; age
             50+ or ≤10 years younger than earliest PDAC in family at time of diagnosis.
          2. 2 affected first degree relatives with PDAC; age 50+ or 10 years younger than earliest
             PDAC in family
          3. BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely
             pathogenic variant AND 1 first or second degree relative with PDAC; age 50+ or 10
             years younger than earliest PDAC in family
          4. Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely
             pathogenic CDKN2A variant; age 40+
          5. Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant; age 35+
          6. Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history
             of pancreatitis; age 40+
        Cohort 2
        Individuals without history of PDAC meeting any of the following criteria:
          1. ATM, BRCA1, BRCA2, or PALB2 pathogenic or likely pathogenic variant regardless of
             family history, age 50+
          2. 2+ relatives with PDAC on the same side of family, any degree of relation, not meeting
             other criteria above; age 50+ or 10 years younger than earliest PDAC in family
          3. 1 first degree relative with PDAC ≤ age 45; age up to 10 years younger than PDAC
             diagnosis in family member
        Cohort 3 Individual meeting criteria for Cohorts 1 or 2 EXCEPT age (i.e. too young to
        qualify for Cohorts 1 or 2)
        Cohort 4 Individuals without history of PDAC presenting for evaluation who do not meet any
        criteria for 1-3, 6, or the Cyst Cohort.
        Cohort 5 Individuals without history of PDAC who are not otherwise engaged in pancreas
        surveillance at a participating site may be invited to participate in the PRECEDE database
        and to donate a biosample (e.g. blood, saliva, and/or buccal swab) for discovery studies.
        This may include relatives of individuals in Cohorts 1-4,6, and the Cyst Cohort.
        Cohort 6
        Individuals with a personal history of PDAC meeting any of the following criteria:
          1. Family history includes at least one first degree relative with PDAC, or 2 relatives
             with PDAC who are first degree related to each other
          2. Personal or family history of a pathogenic or likely pathogenic germline variant in
             ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11
          3. Diagnosed ≤ age 45
        Cyst Cohort Individuals with a personal history of a pancreatic cystic neoplasm not meeting
        any criteria for Cohorts 1-3 or 6 (no known family history of PDAC, no known pathogenic
        germline variants linked to PDAC risk)
        Exclusion Criteria:
          -  Individuals not meeting the criteria above.